AURKB and neoplasm: AKT was reported to phosphorylate AURKB on threonine 73, which protected it from proteasome degradation in cancer cells, and in PI3K/PTEN pathway altered tumor cell lines that lack a co-existence of KRAS-BRAF mutation are highly addicted to AKT maintenance of AURKB [13].